Prof. Dr. CAVİT BOZ

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, ss.364-365, (Özet Bildiri)

2. Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years

Roberts J., Sharmin S., Horakova D., Havrdova E., Ozakbas S., Lugaresi A., et al.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, ss.357-360, (Özet Bildiri)

3. MULTİPL SKLEROZ TEDAVİSİNDE DİMETİL FUMARATIN İKİ YILLIK TÜRKİYE GERÇEK YAŞAM VERİSİ

TERZİ M., ŞEN S., BECKMANN Y., KARABUDAK R., HELVACI E. M., YETKİN M. F., et al.

59.Ulusal Nöroloji Kongresi, Antalya, Türkiye, 13 - 18 Aralık 2023, (Özet Bildiri)

4. The Effect of Pregnancy on Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Associated Disease Activity and Progression: A Multi-center Retrospective Study from Turkey

Uzunkopru C., Şen S., Altintas A., ÇAKAN ERCAN M., BÜNÜL S. D., Demir G. A., et al.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.664, (Özet Bildiri)

5. AN UNUSUAL REASON OF BACK PAIN AND WEAKNESS: SPINAL CORD INFARCTION

CANDAŞ K. B., KURŞUN S., GÜL K., YÜKSEL Z. Ö., İMAMOĞLU M., ÖZER V., et al.

17th WINFOCUS WORLD CONGRESS & 8th EURASIAN CONGRESS ON EMERGENCY MEDICINE, Türkiye, 1 - 04 Aralık 2022, (Özet Bildiri)

6. GEBELİĞİN NÖROMYELİTİS OPTİKA SPEKTRUM HASTALIĞI (NMOSD) VE MYELİN OLİGODENDROSİT GLİKOPROTEİN İLİŞKİLİ HASTALIK (MOGAD) PROGNOZU ÜZERİNE ETKİLER

UZUNKÖPRÜ C., GÜNDÜZ T., BOZ C., GÜLER S.

58. Ulusal Nöroloji Kongresi (Uluslararası Katılımlı), Antalya, Türkiye, 19 Kasım 2022, (Tam Metin Bildiri)

7. Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study

Butzkueven H., Spelman T., ÖZAKBAŞ S., Laureys G., Van Hijfte L., Alroughani R., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.384-386, (Özet Bildiri)

8. Emulating randomized clinical trials in relapsing-remitting multiple sclerosis with nonrandomized real-world evidence: an application using data from the MSBase registry

Ponzano M., ÖZAKBAŞ S., Horakova D., Havrdova E., Terzi M., Alroughani R., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.379-380, (Özet Bildiri)

9. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Sharmin S., Roos I., Simpson-Yap S., Malpas C., Sanchez M. M., ÖZAKBAŞ S., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.967-970, (Özet Bildiri)

10. Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS

Kalincik T., Sharman S., Roos I., Freedman M., Atkins H., Burman J., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.11-14, (Özet Bildiri)

11. A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis

Roos I., Hughes S., MacDonnell G., Boz C., Alroughani R., Ozakbas S., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.951-953, (Özet Bildiri)

12. Medulla oblongata volume measured from clinical routine T2-FLAIR scans is associated with disability progression in a multiple sclerosis real-world dataset

Bergsland N., Barnett M., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.289-290, (Özet Bildiri)

13. Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

Zhu C., Kalincik T., Horakova D., Zhen Z., Buzzard K., Skibina O., et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, ss.645-647, (Özet Bildiri)

14. Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi-National Registry (P17-4.001)

Kalincik T. K., TERZİ M., TÜRKOĞLU R., BOZ C., ALTINTAŞ A., Malpas C. B. M., et al.

American Academy of Neurology, Seattle, Amerika Birleşik Devletleri, 20 Mayıs 2022, cilt.98, ss.17, (Tam Metin Bildiri)

15. Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis

Spelman T., Acosta C., Hyde R., Campbell N., Havrdova E., Horakova D., et al.

8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 - 13 Eylül 2020, cilt.26, ss.526-527, (Özet Bildiri)

16. Distal Tübüler Asidoz, Osteopetrozis ve Serebral Kalsifikasyonu Olan Bir Vaka,?

KAYNAR R. K., BOZ C., ULUSOY Ş., ÖZMENOĞLU M., Gül S.

4. Ulusal Hipertansiyon ve Böbrek Hastalıkları Kongresi,, Antalya, Türkiye, ss.56, (Tam Metin Bildiri)

17. Distal Tübüler Asidoz, Osteopetrozis ve Serebral Kalsifikasyonu Olan Bir Vaka,?

KAYNAR R. K., BOZ C., ULUSOY Ş., ÖZMENOĞLU M., Gül S.

4. Ulusal Hipertansiyon ve Böbrek Hastalıkları Kongresi,, Antalya, Türkiye, ss.56, (Tam Metin Bildiri)

18. Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis

Kalincik T., Ibrahima D., Malpas C., Horakova D., Havrdova E., Trojano M., et al.

Annual Meeting of the American-Academy-of-Neurology, Toronto, Kanada, 25 Nisan - 01 Mayıs 2020, (Özet Bildiri)

19. Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)

Sharmin S., Bovis F., Malpas C. B., Horakova D., Trojana M., BOZ C., et al.

American Academy of Neurology, Amerika Birleşik Devletleri, 14 - 26 Nisan 2020, cilt.94, ss.2002, (Tam Metin Bildiri)

20. Identification of Therapeutic Lag in Multiple Sclerosis (1787)

Roos I., Leray E., Frascoli F., Horakova D., Trojana M., ÖZAKBAŞ S., et al.

American Academy of Neurology, Amerika Birleşik Devletleri, 14 - 19 Nisan 2020, cilt.94, ss.1787, (Tam Metin Bildiri)

21. Identification of Therapeutic Lag in Multiple Sclerosis

ROOS I., Leray E., FRASCOLİ F., Casey R., Horakova D., Havrdova E., et al.

Annual Meeting of the American-Academy-of-Neurology, Toronto, Kanada, 25 Şubat - 01 Mart 2020, (Özet Bildiri)

22. Determinants of Therapeutic Lag in Multiple Sclerosis (2059)

Roos I., Leray E., Frascoli F., Horakova D., Trojano M., Patti F., et al.

American Academy of Neurology, Amerika Birleşik Devletleri, 14 - 27 Nisan 2020, cilt.94, ss.2059, (Tam Metin Bildiri)

23. of Therapeutic Lag in Relapsing Multiple Sclerosis

ROOS I., FRASCOLİ F., Horakova D., Havrdova E., Trojano M., Izquierdo G., et al.

Conference of MS-Research-Australia, 31 Ekim - 01 Kasım 2019, (Özet Bildiri)

24. Multipl Skleroz Hastalarında Fingolimod Tedavisinin Etkililiği : Türkiye Gerçek Yaşam Verileri

TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., EKMEKÇİ Ö., et al.

55. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 15 - 21 Kasım 2019, (Özet Bildiri)

25. SS-78 GEÇ VE ERKEN BAŞLANGIÇLI MULTİPLE SKLEROZHASTALARINDA, KLİNİK VE HASTALIK PROGRESYONUFARKLILIKLARI

ZENGIN KARAHAN S., bilgiç a. b., KARAMAN A. G., BOZ C., TERZİ M.

55. Ulusal Nöroloji Kongresi, Türkiye, 15 - 21 Kasım 2019, (Tam Metin Bildiri)

26. SS-46 OCRELİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİLERİ:3 MULTİPL SKLEROZ MERKEZİNİN TECRÜBELERİ

VURAL E., TERZİ M., Sunter G., AĞAN YILDIRIM K., BOZ C.

55. Ulusal Nöroloji Kongresi, Türkiye, 15 Kasım 2018 - 21 Kasım 2019, (Tam Metin Bildiri)

27. BİR ULUSAL ÇALIŞMANIN YÖNTEMİ (ENVIROPIMS): YENİ TANI ALMIŞ ERİŞKİN, ERGEN VE ÇOCUK MULTİPLE SKLEROZ(MS) OLGULARINDA OBEZİTE, SAĞLIKLI BESLENME VE FİZİKSEL AKTİVİTE DURUMUNUN ARAŞTIRILMASI

YÜCEYAR A. N., AKMAN DEMİR G., ALTUNRENDE B., BECKMANN Y., BOZ C., CANBAZ KABAY S., et al.

55. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 15 - 21 Kasım 2019, (Özet Bildiri) Sürdürülebilir Kalkınma

28. TEP-147 MULTİPL SKLEROZ HASTALARINDA FİNGOLİMODTEDAVİSİNİN ETKİLİLİĞİ : TÜRKİYE GERÇEK YAŞAMVERİLERİ (REFINE)

TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., Ekmekci Ö., et al.

55. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 16 - 20 Kasım 2019, ss.276, (Özet Bildiri)

29. SS-77 BİR ULUSAL ÇALIŞMANIN YÖNTEMİ (ENVIROPIMS):YENİ TANI ALMIŞ ERİŞKİN, ERGEN VE ÇOCUK MULTİPLESKLEROZ(MS) OLGULARINDA OBEZİTE, SAĞLIKLIBESLENME VE FİZİKSEL AKTİVİTE DURUMUNUNARAŞTIRILMASI

YÜCEYAR A. N., AKMAN G., ALTUNRENDE B., BECKMANN Y., BOZ C., CANBAZ KABAY S., et al.

55. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 16 - 20 Kasım 2019, ss.45, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

30. Self-management and coping strategies in patients with multipl sclerosia multicenter -prospective study

BOZ C., ÜNAL A., AKÇALI A., ALTUNRENDE B.

ECTRIMS, 11 - 13 Eylül 2019, (Özet Bildiri)

31. Real-world experience with Ocrelizumab in the MSBase Registry

Butzkueven H., Spelman T., Patti F., Ozakbas S., Eichau S., Alroughani R., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.539-540, (Özet Bildiri)

32. Modifiers of the effectiveness of MS immunotherapies

Kalincik T., Malpas C., Sharmin S., Horakova D., Havrdova E. K., Trojano M., et al.

33. Determinants of therapeutic lag in relapsing multiple sclerosis

Roos I., Frascoli F., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., et al.

34. Real-life outcomes of Ocrelizumab treatment from 3 multiple sclerosis centers in Turkey

Vural E., Terzi M., Sunter G., Gunal D., Agan K., Boz C.

35. MS cohorts and treatment utilization in academic centres in the Middle East

Moradi N., Sharmin S., Malpas C., Ozakbas S., Shaygannejad V., Alroughani R., et al.

36. Therapeutic lag in relapsing multiple sclerosis

Roos I., Frascoli F., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., et al.

37. Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression

De Brouwer E., Peeters L., Becker T., Altintas A., Soysal A., Van Wijmeersch B., et al.

38. Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up

Boz C., Terzi M., Ozakbas S., Yuceyar N., Efendi H., Balci B. P., et al.

39. Aggressive form of multiple sclerosis can be predicted early after disease onset

Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., et al.

40. Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data

Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., et al.

41. Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

Sharmin S., Lefort M., Andersen J., Horakova D., Havrdova E. K., Alroughani R., et al.

42. Multiple Sclerosis Severity Score (MSSS) helps predict relapses and recovery from disability in patients treated for multiple sclerosis in the MSBase model

Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., Havrdova E. K., et al.

43. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS

Kalincik T., Malpas C. B., Sharmin S., Roos I., Patti F., Butzkueven H., et al.

44. Predicting long-term sustained disability progression in multiple sclerosis

Sharmin S., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., Eichau S., et al.

45. Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Kunchok A., Malpas C., Nytrova P., Havrdova E., Alroughani R., TERZİ M., et al.

71st Annual Meeting of the American-Academy-of-Neurology (AAN), Pennsylvania, Amerika Birleşik Devletleri, 4 - 10 Mayıs 2019, cilt.92, (Özet Bildiri)

46. MULTİPL SKLEROZDA FİNGOLİMOD TEDAVİSİ SONRASI GELİŞEN GEBELİĞİN HASTALIK SEYRİNE OLAN ETKİSİ

TERZİ M., EVİN Ö., BOZ C., ONAR M. K.

MS DAYS V, KYRENIA, 2 - 04 Kasım 2018, ss.15, (Tam Metin Bildiri)

47. Determinants of disability accumulation in secondary-progressive multiple sclerosis

Lizak N., Malpas C., Sharmin S., Havrdova E., Horakova D., Izquierdo G., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.30, (Tam Metin Bildiri)

48. Familial multiple sclerosis: comparing demographic and clinical characteristics with sporadic form

Eichau S., Spelman T., Izquierdo G., Laffaldano P., OrejaGuevara C., Butzkueven H., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.31, (Tam Metin Bildiri)

49. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry

Spelman T., Havrdova E., Horakova D., Izquierdo G., Kalincik T., Lugaresi A., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.31, (Tam Metin Bildiri)

50. RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the ’xxRELOMS-T’xx

SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., et al.

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Almanya, 10 - 12 Ekim 2018, ss.100, (Özet Bildiri)

51. RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the 'RELOMS-T'

Sevim S., Demirkiran M., Terzi M., Yuceyar A. N., Tasdelen B., Idiman E., et al.

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.174, (Özet Bildiri)

52. Variability in scoring the functional system scores of the expanded disability status scale at clinics from different countries

Hum S., Brown R., Lapierre Y., Fellows L., Mayo N., Havrdova E. K., et al.

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.155-156, (Özet Bildiri)

53. Methylprednisolone concentration in milk and serum during and shortly after IV pulse therapy in patients with MS

Boz C., Ozer B., Terzi M., Karahan S. Z., Sen S., Mavis M., et al.

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.978, (Özet Bildiri)

54. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.

Spelman T., Harvrdova E. K., Horakova D., Izquierdo G., Kalincik T., Lugaresi A., et al.

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Almanya, 10 - 12 Ekim 2018, cilt.24, ss.25-26, (Özet Bildiri)

55. Investigation of the Clinical and Morphometric Changes Before and After Acupuncture Treatment in Patients with Bell’s Paralysis

ERTEMOĞLU ÖKSÜZ C., KALAYCIOĞLU A., YILDIRIM A., UZUN Ö., KALKIŞIM Ş. N., BOZ C., et al.

1.Uluslararası Geleneksel ve Tamamlayıcı Tıp Kongresi, 19 - 22 Nisan 2018, (Tam Metin Bildiri)

56. Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry

Kister I., Bacon T., Shaygannejad V., Havrdova E., Alroughani R., TERZİ M., et al.

70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)

57. A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

Spelman T., Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., et al.

70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)

58. Let's raise the awareness of MS specialists concerning the frequency and impact of RLS in MS and consequently the life quality of patients with MS: Striking results of the 'RELOMS-T' Study

Sevim S., Demirkiran M., TERZİ M., Yuceyar N., Tasdelen B., İDİMAN E., et al.

70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)

59. Susac Syndrome: Clinical Features, Laboratory Testing and Treatment Responses of 3 Cases

Ozmenoglu M., Karahan S. Z., Usta N. C., BOZ C.

10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 Kasım 2017, cilt.24, ss.421, (Özet Bildiri)

60. De Novo Trigeminal Neuralgia Induced by Dalfampridine (4-aminopyridine):3 Cases

Ozmenoglu M., BOZ C., Seker D., Horozoglu H.

10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 Kasım 2017, cilt.24, ss.379, (Özet Bildiri)

61. Multipl Skleroz artık HBS sekonder nedenleri arasında yerini almalı: Bu alanda şimdiye kadar yapılmış en geniş çaplı çalışmanın (Multipl sklerozun huzursuz bacakları-Türkiye) (RELOMS-T)) çarpıcı sonuçları

SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., et al.

53. Ulusal Nöroloji Kongresi, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)

62. MULTİPL SKLEROZDA FAMPRİDİNE TEDAVİSİ SONRASI TRİGEMİNAL NEVRALJİ

TERZİ M., BOZ C., ŞENER M., BEKIR Ö., ŞEN S.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)

63. MULTIPL SKLEROZ’DA MORTALİTE

TERZİ M., BOZ C., KIZILATEŞ G., ŞEN S., BEKIR Ö.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)

64. Susac Syndrome: Clinical features, Laboratory Testing and Treatment Response of 3 cases

ÖZMENOĞLU M., ZENGİN KARAHAN S., CAN USTA N., BOZ C.

10th Congress of the Pan-Asian Committe for Treatment and Research in Multiple Sclerosis, 23 - 25 Kasım 2017, (Tam Metin Bildiri)

65. Ms Tedavisinde Kullanılan İlaçların Kesilme Oranları ve Nedenleri

Çağlar Okumuş A., BOZ C., TERZİ M., ÖZAKBAŞ S., Türkoğlu R., Soysal A., et al.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)

66. Orta ve Doğu Karadeniz Bölgesinde Pediyatrik ve Yetişkin Multipl Skleroz Hastalarının Demografik ve Klinik Özellikleri

Şipal C., Akçaoğlu Y., BOZ C., TERZİ M.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.87, (Özet Bildiri)

67. MULTIPL SKLERODA DİMETİL FUMARAT TEDAVİSİ GERÇEK YAŞAM VERİSİ

TERZİ M., BOZ C., ŞEN S., GÜLER S., ÇİLİNGİR V., ŞENER M.

53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.229, (Özet Bildiri)

68. MULTİPL SKLEROZ’DA NATALİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİSİ

TERZİ M., BOZ C., ÇİLİNGİR V., ŞEN S., ŞENER M., GÜLER S.

53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.229-230, (Özet Bildiri)

69. MULTİPL SKLEROZ HASTALARINDA GLATİRAMER ASETAT TEDAVİSİNİN GÜNLÜK VE HAFTADA 3 KULLANIMI İLAÇ MEMNUNİYETİ

TERZİ M., BOZ C., BİLGE N., ÇİLİNGİR V., BEKIR Ö., BIÇAKCI D., et al.

53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.230-231, (Özet Bildiri)

70. MS TEDAVİSİNDE KULLANILAN İLAÇLARIN KESİLME ORANLARI VE NEDENLERİ

ÇAĞLAR OKUMUŞ A., BOZ C., TERZİ M., ÖZAKBAŞ S., TÜRKOĞLU R., SOYSAL A., et al.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.293, (Özet Bildiri)

71. MS TEDAVİSİNDE TERİFLUNOMİDE VE FİNGOLUMOD’UN KARŞILAŞTIRMALI ETKİNLİK VERİLERİ

BOZ C., ÖZAKBAŞ S., TERZİ M., TÜRKOĞLU R., SOYSAL A., TUNCER M. A., et al.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.54-55, (Özet Bildiri)

72. MS Tedavisinde Teriflunomide ve Fingolimod’un Karşılaştırmalı Etkinlik Verileri

BOZ C., ÖZAKBAŞ S., TERZİ M., Türkoğlu R., Soysal A., TUNCER M. A., et al.

53. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 24 - 30 Kasım 2017, ss.54, (Özet Bildiri)

73. MULTİPL SKLEROZDA MORTALİTE

TERZİ M., BOZ C., KIZILATEŞ EVİN G., ŞEN S., BEKİR Ö.

53. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 24 - 30 Kasım 2017, ss.53, (Özet Bildiri)

74. MULTİPL SKLEROZ ARTIK HBS SEKONDER NEDENLERİ ARASINDA YERİNİ ALMALI!: BU ALANDA ŞİMDİYE KADAR YAPILMIŞ EN GENİŞ ÇAPLI ÇALIŞMANIN [MULTİPL SKLEROZUN HUZURSUZ BACAKLARI-TÜRKİYE (RELOMS-T)] ÇARPICI SONUÇLARI

SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., et al.

53. ULUSAL NÖROLOJİ KONGRE, Türkiye, 24 Kasım 2017 - 30 Ocak 2018, ss.54, (Özet Bildiri)

75. Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis

Kister A., Spelman T., Patti A., duguette A., TROJANO M., Izquierdo G., et al.

MULTIPLE SCLEROSIS JOURNAL, Paris, Fransa, 25 - 28 Ekim 2017, (Özet Bildiri)

76. METHYLPREDNİSOLONE CONCENTRATİONS İN BREAST MİLK AND SERUM İN PATİENT WİTH MULTİPLE SCLEROSİS TREATED IV PULSE METHYLPREDNİSOLONE

BOZ C., TERZİ M., KARAHAN S., ŞEN S., SARAÇ Y., MAVİŞ E.

ECTRIMS 2017, 25 - 28 Ekim 2017, (Özet Bildiri)

77. Prognostic value of MRI activity in treatment failure

Kunchok A. C., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.988-990, (Özet Bildiri)

78. Methylprednisolone concentrations in breast milk and serum in patients with multiple sclerosis treated with IV pulse methylprednisolone

Boz C., Terzi M., Karahan S. Z., Ozbudun B., Sen S., Sarac Y., et al.

79. Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis

Jokubaitis V. G., Havrdova E., Horakova D., Izquierdo G., Kalincik T., van der Walt A., et al.

80. Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years

Kalincik T., Spelman T., Jokubaitis V., Horakova D., Havrdova E., Trojano M., et al.

81. Silent lesions on MRI - shifting goal post for treatment decisions in MS

Min M., Lechner-Scott J., Spelman T., Sola P., Granella F., Butzkueven H., et al.

82. Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis

Boz C., Ozakbas S., Terzi M., Turkoglu R., Akman G., Efendi H., et al.

83. The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis

Brown J. W. L., Lugaresi A., Horakova D., Havrdova E., Jokubaitis V., Lechner-Scott J., et al.

84. Contribution of inflammation to disability accrual in primary progressive multiple sclerosis

Hughes J., Jokubaitis V., Spelman T., Lugaresi A., Hupperts R., Izquierdo G., et al.

85. Susac syndrome: clinical features, laboratory testing and treatment responses of 20 cases

Karahan S. Z., Boz C., Usta N. C., Saip S., Kale N., Demirkaya S., et al.

86. Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis

Merkel B., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., et al.

87. Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

Kalincik T., Spelman T., Jokubaitis V., Horakova D., Havrdova E., Izquierdo G., et al.

88. Risk of secondary progressive multiple sclerosis: a longitudinal study

Fambiatos A., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., et al.

89. A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS

Spelman T., Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., et al.

90. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis

Boz C., Terzi M., Karahan S. Z., Sen S., Sarac Y., Mavis M.

3rd Congress of the European-Academy-of-Neurology, Amsterdam, Hollanda, 01 Haziran 2017, cilt.24, ss.490, (Özet Bildiri)

91. Pediatrik başlangıçlı multiple skleroz ile erişkin başlangıçlı multiple sklerozun klinik özelliklerinin karşılaştırılması

KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DURGUT B. D., DİLBER B., et al.

19. Ulusal Çocuk Nörolojisi Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)

92. Pediatrik başlangıçlı multipl skleroz ile erişkin başlangıçlı multipl sklerozun klinik özelliklerinin karşılaştırılması.

KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., et al.

19. Ulusal Çocuk Nörolojisi Kongresi, Kıbrıs (Kktc), 19 - 23 Nisan 2017, (Özet Bildiri)

93. Spinal anestezi sonrası gelişen unilateral abducens sınır paralizisi

KARAMAN A., GAZİOĞLU S., GÜRSOY M., ALTUNAYOĞLU ÇAKMAK V., BOZ C.

52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016, (Özet Bildiri)

94. TEP 147 MS Tedavisinde Teriflunomide in Etkinlik ve Tolerabite Gerçek Yaşam Verileri

BOZ C., TERZİ M., TÜRKOĞLU R., AKMAN G., EFENDİ H., AKÇALI A., et al.

52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016

95. Wernicke ensefalopatisi: olgu sunumu

GÜRSOY M., AKPINAR R., ALTUNAYOĞLU ÇAKMAK V., BOZ C., GAZİOĞLU S.

52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016, (Özet Bildiri)

96. T1-T2 radikülopatiye bağlı horner sendromu olgusu

ŞENER S., ÖZTÜRK S., GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., BOZ C.

52. Ulusal Nöroloji Kongresi, Türkiye, 25 Kasım - 01 Aralık 2016, (Özet Bildiri)

97. Anti inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosisAuthor s J Lorscheider V Jokubaitis T Spelman G Izquierdo A Lugaresi E Havrdova D Horakova M Trojano P Duquette M Girard A Prat F Grand Maison R Hupperts P Grammond E Pucci C Boz P Sola D Spitaleri J Lechner Scott M Terzi V Van Pesch G Iuliano R Bergamaschi R Fernández Bolaños C Ramo Tello F Granella M E Rio C Oreja Guevara H Butzkueven T Kalincik MSBase Study Group

Lorscheider l., jocubatis v., spelman t., Izquierdo g., lugaresi a., hardova e., et al.

ECTRIMS 2016, 14 - 16 Eylül 2016, (Özet Bildiri)

98. Individual response to disease modifying therapies a global observational cohort studyAuthor s T Kalincik L Sobisek V Jokubaitis T Spelman D Horakova E Havrdova M Trojano G Izquierdo A Lugaresi M Girard A Prat P Duquette P Grammond P Sola R Hupperts F Grand Maison E Pucci C Boz R Alroughani V Van Pesch J Lechner Scott M Terzi R Bergamaschi G Iuliano F Granella D Spitaleri V Shaygannejad C Oreja Guevara M Slee R Ampapa F Verheul P McCombe J Olascoaga M P Amato S Vucic S Hodgkinson C Ramo S Flechter E Cristiano C Rozsa F Moore J L Sanchez Menoyo M L Saladino M Barnett H Butzkueven MSBase Study Group

Kalincik t., Sobisek l., jocubatis v., spelman t., Dana H., Eva H., et al.

ECTRIMS 2016, 13 - 16 Eylül 2016, (Özet Bildiri)

99. Comparison of 5 year treatment outcomes between alemtuzumab versus natalizumab fingolimod and interferon 1a

Kalincik T., Brown j., Robertson R., Willis m., Scolding N., Pearson O., et al.

ECTRIMS 2016, 13 - 16 Eylül 2016, (Özet Bildiri)

100. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Fragoso Y. D., Alroughani R., Barnett M., Brooks J. B., Butzkueven H., Boz C., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.337-338, (Özet Bildiri)

101. Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis

Lorscheider J., Jokubaitis V., Spelman T., Izquierdo G., Lugaresi A., Havrdova E., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.367-369, (Özet Bildiri)

102. Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a

Kalincik T., Brown J. W., Robertson N., Willis M., Scolding N., Pearson O., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.829-832, (Özet Bildiri)

103. Early disease modifying treatment delays disability accumulation in patients with pediatric onset clinically isolated syndrome suggestive of multiple sclerosis.

Iaffaldano P., Simone M., Lucisano G., Ghezzi A., Coniglio G., Morra V. B., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.62-63, (Özet Bildiri)

104. Real-life data from efficacy of fingolimod treatment in multiple sclerosis patients in Turkey

Terzi M., Kurtuncu M., Eraksoy M., Karabudak R., Tuncer A., Altunrende B., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.310, (Özet Bildiri)

105. Long-term disability trajectories in primary progressivs MS patients - a latent class growth analysis.

Signori A., Izquierdo G., Lugaresi A., Hupperts R., Grand'Maison F., Sola P., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.44-46, (Özet Bildiri)

106. Outcomes of pregnancy in neuromyelitis optica patients: turkish multicenter study data

Altintas A., Uygunoglu U., Terzi M., Boz C., Saip S., Koseoglu M., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.405-406, (Özet Bildiri)

107. Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide

Spelman T., Kalincik T., Trojano M., Grand'Maison F., Izquierdo G., Havrdova E., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.602-603, (Özet Bildiri)

108. Individual response to disease modifying therapies: a global observational cohort study

Kalincik T., Sobisek L., Jokubaitis V., Spelman T., Horakova D., Havrdova E., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.358-360, (Özet Bildiri)

109. Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer

Spelman T., Izquierdo G., Lugaresi A., Alroughani R., Duquette P., Boz C., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.600-602, (Özet Bildiri)

110. Prospectively Tracking DiseaseCourse and Treatment Changes in Neuromyelitis Optica Using NMOBase a Global Online Registry Ilya Kister Tamar Bacon Vahid Shaygannejad JyhYung Hor Raed Alroughani Shannon Haas Murat Terzi Cavit Boz Javier Olascoaga Pamela McCombe Yara Fragoso AlessandraLugaresi Patrizia Sola Steve Vucic EugenioPucci Talal Al Harbi Seyed Aidin Sajedi Juan Ignacio Rojas Liliana Patrucco EdgardoCristiano Jose Alberto Suarez MagdaliniTsolaki Bruce Taylor Gerardo Iuliano Paschalis Devranis Mark Marriott HelmutButzkueven

Kister I., bocan t., Shaygannejad v., Yung Hor j., Alroughani r., Shannon h., et al.

aan2016, 12 - 18 Nisan 2016, (Özet Bildiri)

111. Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry.

Kister I., Bacon T., Shaygannejad V., Hor J. Y., Alroughani R., Haas S., et al.

68th Annual Meeting of the American-Academy-of-Neurology (AAN), Vancouver, Kanada, 15 - 21 Nisan 2016, cilt.86, (Özet Bildiri)

112. Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.

Butzkueven H., Spelman T., Kalincik T., Jokubaitis V., Zhang A., Pellegrini F., et al.

8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul, Güney Kore, 19 - 21 Kasım 2015, cilt.22, ss.418-419, (Özet Bildiri)

113. MS te yeni fenotipik patolojik ve klinik sınıflama

BOZ C.

Ulusal Nöroloji kongresi, Türkiye, 29 Kasım - 01 Aralık 2015

114. RRMS HASTALARINDA 12 AYLIK FİNGOLİMOD TEDAVİSİ SONUÇLARI: FİNE ÇALIŞMASI

AKMAN DEMİR G., Türkoğlu R., SAİP S., YÜCEYAR A. N., EFENDİ H., TURAN Ö. F., et al.

51. ULUSAL NÖROLOJİ KONGRESİ, Türkiye, 27 Kasım - 03 Aralık 2015, (Özet Bildiri)

115. Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity

Spelman T., Izquierdo G., Alroughani R., Fernandez Bolaos R., Havrdova E., Horaova D., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.237-238, (Özet Bildiri)

116. Defining secondary progressive multiple sclerosis

Lorscheider J., Buzzard K., Jokubaitis V., Spelman T., Havrdova E., Horakova D., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.798-800, (Özet Bildiri)

117. 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

Jokubaitis V. G., Spelman T., Kalincik T., Travaglini D., Paolicelli D., Duquette P., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.100-102, (Özet Bildiri)

118. Lack of association between pulse steroid therapy and bone mineral density in patients with multiple sclerosis

KARAHAN S. C., BOZ C., USTA N. C., KILIC S., Ozmenoglu M., Altunayoglu V., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.773, (Özet Bildiri)

119. Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis

Stewart T., Jokubaitis V., Spelman T., Havrdova E., Horakova D., Trojano M., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.726-728, (Özet Bildiri)

120. Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS

Spelman T., Kalincik T., Jokubaitis V., Zhang A., Pellegrini F., Wiendl H., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.258-259, (Özet Bildiri)

121. Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis

Lizak N., Lugaresi A., Alroughani R., Lechner-Scott J., Slee M., Havrdova E., et al.

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, İspanya, 7 - 10 Ekim 2015, cilt.21, ss.308-310, (Özet Bildiri)

122. Neuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort: demographic, clinical, laboratory and radiological features

Altintas A., Karabudak R., Balci B. P., Terzi M., Soysal A., Saip S., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.348-349, (Özet Bildiri)

123. Comparison of fingolimod versus interferon beta/glatiramer acetate as second-line therapy in active multiple sclerosis

He A., Spelman T., Jokubaitis V., Lugaresi A., Izquierdo G., Trojano M., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.193, (Özet Bildiri)

124. Evaluation of common criteria of progression of disability in a large observational cohort

Kalincik T., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.62-63, (Özet Bildiri)

125. Independent predictors of time to relapse after CIS in high-risk patients

Spelman T., Meyniel C., Trojano M., Lugaresi A., Izquierdo G., Grand'Maison F., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.54, (Özet Bildiri)

126. NMOBase is a Web-based, global observational registry for an 'orphan' disorder: neuromyelitis optica

Kister I., Bacon T., Alroughani R., Boz C., Cristiano E., Iuliano G., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.165, (Özet Bildiri)

127. Predictors of disability accrual in multiple sclerosis patients on first-line therapy

Spelman T., Jokubaitis V., Izquierdo G., Duquette P., Grand'Maison F., Grammond P., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.405, (Özet Bildiri)

128. Seasonal variation of relapse rate in MS is latitude-dependent

Spelman T., Gray O., Trojano M., Petersen T., Izquierdo G., Lugaresi A., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.218-219, (Özet Bildiri)

129. Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, Amerika Birleşik Devletleri, 10 - 13 Eylül 2014, cilt.20, ss.195-196, (Özet Bildiri)

130. Rekürrenslerle giden ADEM Guillain Barre Sendromu birlikteliği: Olgu Sunumu

ŞAHİN S., KAMAŞAK T., Baba Ö., CANSU A., BOZ C.

16. Ulusal Çocuk Nöroloji Kongresi, Türkiye, 22 - 27 Haziran 2014, (Özet Bildiri)

131. Head-to-head Comparisons of Interferon Beta and Glatiramer Acetate in Clinical Practice

Butzkueven H., Kalincik T., Jokubaitis V., Izguierdo G., Duquette P., Girard M., et al.

6th Congress of the Pan-Asian-Committee-on-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Kyoto, Japonya, 6 - 08 Kasım 2013, cilt.20, ss.927, (Özet Bildiri)

132. Factors associated with early hospital arrival in acute ischemic stroke patients

Koksal E. K., Gazioglu S., Boz C., Can G., Alioglu Z.

Joint Congress of European Neurology, İstanbul, Türkiye, 31 Mayıs - 03 Haziran 2014, cilt.21, ss.353, (Özet Bildiri)

133. Factors associated with early hospital arrival in acute ischemic stroke patients

Koksal E. K., Gazioglu S., Boz C., Can G., Alioglu Z.

Joint Congress of European Neurology, İstanbul, Türkiye, 31 Mayıs - 03 Haziran 2014, cilt.261, (Özet Bildiri)

134. Multipl Skleroz hastalarında kişilik özellikleri ve klinik özelliklerle ilişkisi

GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ÖZKORUMAK KARAGÜZEL E., CAN USTA N., BOZ C.

49. Ulusal Nöroloji Kongresi, Trabzon, Türkiye, 15 - 21 Kasım 2013

135. Multipl Skleroz hastalarında kisilik özellikleri ve klinik özelliklerle iliskisi

GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ÖZKORUMAK KARAGÜZEL E., USTA N. C., BOZ C.

49. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 15 - 21 Kasım 2013, ss.108, (Tam Metin Bildiri)

136. Huzursuz bacaklar sendromlu hastaların mizaç ve karakter özellikleri

ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S., ÖZKORUMAK KARAGÜZEL E., USTA N. C., TOPBAŞ M., BOZ C.

14. Ulusal Uyku Tıbbı Kongresi, Muğla, Türkiye, 6 - 10 Ekim 2013, ss.9, (Tam Metin Bildiri)

137. Relapse incidence in women and men throughout the course of multiple sclerosis: an MSBase cohort study

Kalincik T., Vivek V., Jokubaitis V., Lechner-Scott J., Trojano M., Izquierdo G., et al.

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Danimarka, 2 - 05 Ekim 2013, cilt.19, ss.28-30, (Özet Bildiri)

138. Predictors of 12-month confirmed disability progression after onset of clinically isolated syndrome (CIS) suggestive of multiple sclerosis

Jokubaitis V. G., Spelman T., Trojano M., Izquierdo G., Grand'Maison F., Duquette P., et al.

139. Symptomatology of multiple sclerosis relapses varies in relation to demographic and clinical factors

Kalincik T., Buzzard K., Trojano M., Duquette P., Girard M., Izquierdo G., et al.

140. Head-to-head comparisons of preparations of interferon beta and glatiramer acetate: a series of quasi-randomised MSBase trials

Kalincik T., Trojano M., Izquierdo G., Duquette P., Girard M., Grammond P., et al.

141. Defining secondary progressive multiple sclerosis: is it possible to diagnose early?

Spelman T., Trojano M., Duquette P., Izquierdo G., Lugaresi A., Grammond P., et al.

142. Does switching to fingolimod from natalizumab result in short-term relapse exacerbation?

Jokubaitis V. G., Li V., Kalincik T., Izquierdo G., Hodgkinson S., Alroughani R., et al.

143. Clinical And Radiological Characteristics Of Tumefactive Demyelinating Lesions: Follow-up Study

Altintas A., Petek B., Isik N., Terzi M., Bolukbasi F., Tavsanli M., et al.

5th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Beijing, Çin, 13 - 15 Eylül 2012, cilt.19, ss.656, (Özet Bildiri)

144. PREDICTORS OF POSTPARTUM RELAPSES IN WOMEN WITH MULTIPLE SCLEROSIS: RESULTS FROM THE MSBASE REGISTRY

Hughes S. E., Spelman T., Gray O. M., Boz C., Trojano M., McDonnell G. V., et al.

Annual Meeting of the Association-of-British-Neurologists, Brighton, İngiltere, 28 - 31 Mayıs 2012, cilt.83, (Özet Bildiri)

145. EXPOSURE TO INTERFERON-beta THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS

Hughes S., Spelman T., Gray O., Boz C., Trojano M., Zwanikken C., et al.

Annual Meeting of the Association-of-British-Neurologists, Brighton, İngiltere, 28 - 31 Mayıs 2012, cilt.83, (Özet Bildiri)

146. Risk factors of reduced bone mass in patients with multiple sclerosis

Boz C., Karahan S. Z.

28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, Fransa, 10 - 13 Ekim 2012, cilt.18, ss.249, (Özet Bildiri)

147. Male MS patients fare worse!

Ribbons K. A., McElduff P., Vetere S., Boz C., Trojano M., Zwanikken C., et al.

28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, Fransa, 10 - 13 Ekim 2012, cilt.18, ss.79-80, (Özet Bildiri)

148. Seasonal variation of relapse rate and ultraviolet radiation levels are sinusoidal and their phase-shifted relationship is latitude-dependent

Spelman T., Gray O., Trojano M., Lugaresi A., Izquierdo G., Zwanikken C., et al.

28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, Fransa, 10 - 13 Ekim 2012, cilt.18, ss.83-84, (Özet Bildiri)

149. Multiple sklerozda huzursuz bacaklar sendromu

ALTUNAYOĞLU ÇAKMAK V., CANATAN S., GAZİOĞLU S., BOZ C.

47. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 25 Kasım - 01 Aralık 2011, ss.68, (Tam Metin Bildiri)

150. Multiple skleroz hastalarında uykusuzluk ve özellikleri

ALTUNAYOĞLU ÇAKMAK V., CANATAN S., GAZİOĞLU S., BOZ C.

47. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 25 Kasım - 01 Aralık 2011, ss.67, (Tam Metin Bildiri)

151. Predictors of Confirmed Disability Progression after a First Demyelinating Event

Butzkueven H., Spelman T., Izquierdo G., Grand-Maison F., Trojano M., Zwanikken C., et al.

63rd AAN Annual Meeting, Hawaii, Amerika Birleşik Devletleri, 9 - 16 Nisan 2011, cilt.76, (Özet Bildiri)

152. Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study

Eraksoy M., Akman-Demir G., Agan K., Gunal D., Us O., Saip S., et al.

19th World Congress of Neurology, Bangkok, Tayland, 24 - 30 Ekim 2009, cilt.285, (Özet Bildiri)

153. Onset of relapses in multiple sclerosis: the effect of seasonal change in both the northern and southern hemisphere

Gray O., Jolley D., Gibson K., Trojano M., Zwanikken C., Grand'Maison F., et al.

25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Düsseldorf, Almanya, 9 - 12 Eylül 2009, cilt.15, (Özet Bildiri)

154. Temporal Variation of Onset of Relapses in Multiple Sclerosis: Results from the Northern and Southern Hemispheres in the MSBase Registry

Gray O. M., Jolley D., Zwanikken C., Trojano M., Grand-Maison F., Duquette P., et al.

61st Annual Meeting of American-Academy-of-Neurology, Washington, Amerika Birleşik Devletleri, 28 - 29 Nisan 2009, cilt.72, (Özet Bildiri)

155. Temporal variation of onset of relapses in multiple sclerosis is not seasonal: results from the MSBase registry

Gray O. M., Jolley D., Zwanikken C., Trojano M., Grand'Maison F., Duquette P., et al.

1st Congress of Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Kuala-Lumpur, Malezya, 21 - 22 Kasım 2008, cilt.15, ss.137-138, (Özet Bildiri)

156. The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis

Gray O. M., Zwanikken C., Trojano M., Grand'Maison F., Duquette P., Grammond P., et al.

1st Congress of Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Kuala-Lumpur, Malezya, 21 - 22 Kasım 2008, cilt.15, ss.140, (Özet Bildiri)

157. The Multiple Sclerosis Severity Score re-examined: Expanded Disability Status Scale rank stability in the MSBase dataset increases five years after onset of multiple sclerosis

Butzkueven H., Jolley D., Trojano M., Zwanikken C., Maison F. G., Duquette P., et al.

13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Kanada, 17 - 20 Eylül 2008, cilt.14, (Özet Bildiri)

158. Reduced effectiveness of long-term interferon beta treatment on relapses in neutralising antibody-positive multiple sclerosis patients: a Canadian MS clinic-based study

Oger J., Boz C., Devonshire V., Hashimoto S., Hooge J., Kastrukoff L., et al.

23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS, Prague, Çek Cumhuriyeti, 11 - 14 Ekim 2007, cilt.13, (Özet Bildiri)

159. Tumefactive demyelinating disease is immunologically different from multiple sclerosis

Boz C., Gazioglu S., Terzi M.

160. Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression.

Butzkueven H., Mechati S., Hoffmann M. W., Arruda W., Boz C., Bacile E., et al.

59th Annual Meeting of the American-Academy-of-Neurology, Massachusetts, Amerika Birleşik Devletleri, 28 Nisan - 05 Mayıs 2007, cilt.68, (Özet Bildiri)

161. Bilateral talamik infaktlarda klinik ve radyolojik bulgular

GAZİOĞLU S., BOZ C., ALTUNAYOĞLU ÇAKMAK V.

42. Ulusal Nöroloji Kongresi, Antalya, Türkiye, 12 - 17 Kasım 2006, ss.169, (Tam Metin Bildiri)

162. Is the current trial definition of confirmed disability progression in multiple sclerosis an accurate measure of permanent disease progression?

Butzkueven H., Mechati S., Hoffmann M., Arruda W. O., Bacile E., Boz C., et al.

22nd Congress of the European-Committee-for-the-Treatment-and-Resarch-in-Multiple-Sclerosis, Madrid, İspanya, 27 - 30 Eylül 2006, cilt.12, (Özet Bildiri)

163. The MSBase Global Web Registry: joining independent local patient databases for multi-centre research

Butzkueven H., Arruda W., Boz C., Chapman J., Cristiano E., Fiol M., et al.

18th World Congress of Neurology, Sydney, Avustralya, 5 - 11 Kasım 2005, cilt.238, (Özet Bildiri)

164. Economic impact of primary headaches in Turkey: a university hospital-based study, part II

Karly N., Zarifoglu M., Ertas M., Saip S., Ozturk V., Bycakcy P., et al.

22nd Congress of the International-Headache-Society, Kyoto, Japonya, 9 - 12 Ekim 2005, cilt.25, ss.951, (Özet Bildiri)

165. The MSBase Global Registry: a web platform for collaborative multiple sclerosis outcomes research

Butzkueven H., Arruda W., Boz C., Chapman J., Cristiano E., Deri N., et al.

21st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/10th Annual Meeting of Rehabilitation in MS, Thessaloniki, Yunanistan, 28 Eylül - 01 Ekim 2005, cilt.11, (Özet Bildiri)